NCT00136409 - A Study of Gleevec in Patients With Idiopathic Myelofibrosis or Chronic Myelomonocytic Leukemia (CMML) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

May 31, 2002

Primary Completion Date

August 31, 2005

Study Completion Date

December 31, 2008

Conditions

MyelofibrosisMyeloid MetaplasiaAgnogenic Myeloid MetaplasiaChronic Myelomonocytic Leukemia

Interventions

DRUG

Imatinib mesylate

400mg orally once daily until disease progression or unacceptable side effects

Trial Locations (2)

Dana-Farber Cancer Institute, Boston

Massachusetts General Hospital, Boston